A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

New research indicates that high levels of folate and vitamin B12 may elevate prostate cancer risk, particularly for ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the ...

Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

According to reports circulating last week, the Government is set to kick into the long grass the proposal for a national ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...